Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) CMO Carmen Bozic sold 5,651 shares of the stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $345.28, for a total transaction of $1,951,177.28. Following the sale, the chief marketing officer now directly owns 46,254 shares in the company, valued at $15,970,581.12. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Carmen Bozic also recently made the following trade(s):
On Tuesday, September 19th, Carmen Bozic sold 5,651 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $351.00, for a total transaction of $1,983,501.00.
Vertex Pharmaceuticals Price Performance
NASDAQ:VRTX traded up $2.17 during trading hours on Thursday, hitting $355.14. 670,928 shares of the stock traded hands, compared to its average volume of 1,154,528. The company has a market cap of $91.47 billion, a price-to-earnings ratio of 27.44, a price-to-earnings-growth ratio of 2.55 and a beta of 0.50. Vertex Pharmaceuticals Incorporated has a 1 year low of $282.21 and a 1 year high of $367.00. The stock has a 50 day moving average price of $348.99 and a 200 day moving average price of $340.90. The company has a quick ratio of 3.96, a current ratio of 4.14 and a debt-to-equity ratio of 0.03.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its earnings results on Tuesday, August 1st. The pharmaceutical company reported $3.53 earnings per share for the quarter, beating analysts’ consensus estimates of $3.47 by $0.06. The company had revenue of $2.49 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Vertex Pharmaceuticals had a net margin of 35.40% and a return on equity of 24.05%. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 13.26 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. 888 reaffirmed a “reiterates” rating on shares of Vertex Pharmaceuticals in a research report on Monday, June 26th. Oppenheimer reaffirmed an “outperform” rating and set a $410.00 price target on shares of Vertex Pharmaceuticals in a report on Wednesday, August 2nd. Evercore ISI boosted their target price on Vertex Pharmaceuticals from $375.00 to $379.00 in a research report on Monday, June 26th. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, September 11th. Finally, Sanford C. Bernstein boosted their price objective on shares of Vertex Pharmaceuticals from $380.00 to $390.00 and gave the company an “outperform” rating in a report on Wednesday, August 2nd. Six research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $367.23.
Hedge Funds Weigh In On Vertex Pharmaceuticals
Hedge funds have recently made changes to their positions in the business. Independence Bank of Kentucky purchased a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $25,000. ST Germain D J Co. Inc. purchased a new position in shares of Vertex Pharmaceuticals in the second quarter worth $26,000. Sandy Spring Bank boosted its position in shares of Vertex Pharmaceuticals by 1,014.3% during the first quarter. Sandy Spring Bank now owns 78 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 71 shares during the last quarter. Marquette Asset Management LLC purchased a new position in Vertex Pharmaceuticals during the second quarter valued at $27,000. Finally, Quent Capital LLC increased its holdings in Vertex Pharmaceuticals by 91.1% in the 2nd quarter. Quent Capital LLC now owns 86 shares of the pharmaceutical company’s stock valued at $30,000 after acquiring an additional 41 shares during the last quarter. Institutional investors own 90.77% of the company’s stock.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations.